-
2-Hydroxypropyl-β-cyclodextrin Protocol
2026-08-10
2-Hydroxypropyl-β-cyclodextrin (SKU B6413) is a cyclic oligosaccharide solubilizer for poorly water-soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. This dossier-based guide supports formulation and biochemical solubility workflows, but does not establish compound-specific efficacy, pharmacokinetics, toxicity, or uses outside solubilization and excipient applications.
-
Dacomitinib (PF-00299804) Research Workflow
2026-08-09
Build a rigorous Dacomitinib workflow that connects irreversible pan-HER signaling blockade with receptor phosphorylation, cell-cycle, apoptosis, and mitochondrial stress readouts. The approach is especially useful for EGFR-mutant lung cancer models, resistant HER2-amplified systems, and carefully controlled exploratory studies of ferroptosis biology.
-
ECE-1c Stability, CK2, and Cisplatin Resistance
2026-08-08
Almarza et al. show that preventing Lys-6 ubiquitination stabilizes ECE-1c and promotes stemness, cisplatin resistance, and invasion in non-small cell lung cancer models. The findings connect CK2-dependent ECE-1c regulation with a non-canonical, endothelin-1-independent aggressive phenotype and provide a rationale for testing silmitasertib as a mechanistic CK2 probe.
-
Diclofenac: COX Inhibition in Organoid Research
2026-08-07
Diclofenac is a non-selective COX inhibitor used to investigate prostaglandin biology, inflammation signaling, and pain signaling research. Its defined physicochemical profile can support reproducible assays, while human pluripotent stem cell-derived intestinal organoids provide a complementary platform for pharmacokinetic studies.
-
Cyclophosphamide as an Alkylating Chemotherapeutic Agent: Wo
2026-08-07
Cyclophosphamide distinguishes itself as a DNA cross-linking cytotoxic compound and immunosuppressive agent, central to both apoptosis induction in cancer cells and bone marrow transplantation conditioning. This guide delivers actionable workflow optimizations, literature-backed protocol parameters, and troubleshooting strategies to maximize reproducibility and translational impact with APExBIO’s Cyclophosphamide.
-
Topotecan as a Novel Topoisomerase I Inhibitor in Cancer Tre
2026-08-06
This article reviews the pharmacological innovation and clinical experience with topotecan, a water-soluble camptothecin analogue that selectively inhibits topoisomerase I, inducing apoptosis in cancer cells. The findings highlight topotecan's unique mechanism, pharmacokinetics, and evidence-based efficacy in various solid tumors, providing critical insight for optimizing chemotherapeutic regimens and advancing cancer research.
-
Everolimus (RAD001): Applied mTOR Inhibition in Cancer Model
2026-08-06
Everolimus (RAD001) stands out as a robust, orally bioavailable mTOR inhibitor, enabling precise dissection of cancer cell proliferation and death in both in vitro and in vivo studies. This article details advanced workflows, troubleshooting strategies, and protocol optimizations for leveraging Everolimus in translational cancer research, grounded in the latest assay innovations.
-
3-Methyladenine for Autophagy Research: Practical Workflows
2026-08-05
3-Methyladenine (3-MA) is a gold-standard autophagy inhibitor, enabling precise dissection of PI3K-dependent pathways in cardiovascular, cancer, and metabolic research. This article translates breakthrough findings into actionable protocols, troubleshooting guidance, and comparative insights for advanced experimental design.
-
Cyclo (-RGDfC): Optimizing Integrin αvβ3 Targeting Workflows
2026-08-05
Cyclo (-RGDfC) empowers precise, high-throughput study of integrin-mediated cell adhesion and tumor targeting in advanced hydrogel and cellular assays. This guide unpacks practical integration, troubleshooting, and real-world protocol enhancements that leverage its unique cyclic structure and exceptional specificity.
-
Open-Platform DLP Enables High-Throughput Hydrogel Printing
2026-08-04
The referenced study introduces a low-cost, open-platform digital light printer (OP-DLP) for precise hydrogel fabrication and spatially controlled activation in 96-well formats. This innovation addresses reproducibility and scalability in biomaterials and cell-based research, with broad implications for high-throughput experimental design.
-
Amiloride (MK-870): Applied Workflows for Ion Channel Resear
2026-08-04
Amiloride (MK-870) stands as a gold-standard ENaC and uPAR inhibitor, powering robust sodium channel research, cellular endocytosis modulation, and disease modeling. This guide translates advanced mechanistic insights into workflow-ready protocols, troubleshooting strategies, and actionable enhancements for sodium channel and receptor pathway assays.
-
Mubritinib Reveals OXPHOS Vulnerabilities in AML via Complex
2026-08-03
Baccelli et al. (2019) identify Mubritinib as a potent, selective inhibitor of mitochondrial complex I that induces cytotoxicity in a genetically distinct subset of acute myeloid leukemia (AML) with elevated oxidative phosphorylation (OXPHOS) activity. Their findings reframe the mechanistic utility of Mubritinib from HER2 inhibition to targeting metabolic dependencies in chemotherapy-resistant AML, offering new directions for metabolic intervention.
-
SW033291: A 15-PGDH Inhibitor Elevating Muscle and Stem Cell
2026-08-03
SW033291 stands out as a potent 15-PGDH inhibitor, enabling precise modulation of prostaglandin E2 to drive muscle repair, hematopoietic stem cell expansion, and tissue regeneration research. Protocol-tailored solubility and workflow flexibility make it indispensable for both in vitro and in vivo regenerative studies.
-
Bufuralol Hydrochloride: Human-Relevant β-Adrenergic Modulat
2026-08-02
This article explores how Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist, empowers translational researchers to model human cardiovascular pharmacology with unprecedented fidelity. By integrating mechanistic insight, hiPSC-derived intestinal organoids, and strategic guidance, we illuminate new frontiers in β-adrenergic modulation studies and define best practices for advanced pharmacokinetic workflows.
-
PRMT5 Inhibition Unveils Spliceosomal and Metabolic Weakness
2026-08-01
This study demonstrates that MYCN-amplified neuroblastoma cells exhibit marked sensitivity to PRMT5 inhibition, revealing a unique vulnerability rooted in spliceosomal, epitranscriptomic, and glutamine metabolic regulation. The findings highlight the interplay between altered mRNA splicing, epitranscriptomic control, and metabolic reprogramming, suggesting new avenues for targeted cancer metabolism research.